Neurocrine Biosciences Schedules Conference Call for Q4 2025
Conference Call and Webcast Set for February 11
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced a conference call and webcast to discuss its fourth quarter and year-end 2025 financial results. This exciting event will take place at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 11, 2026. Attendees can expect an insightful discussion on the company's performance and future direction.
The detailed schedule for the conference call and release is as follows:
Schedule Overview
- Press Release Announcement: February 11, 2026, at 1:00 p.m. PT / 4:00 p.m. ET
- Conference Call Start Time: February 11, 2026, at 1:30 p.m. PT / 4:30 p.m. ET
- Domestic Dial-In Number: 800-579-2543
- International Dial-In Number: 785-424-1789
- Conference ID: NBIX
The webcast can be accessed via Neurocrine Biosciences' official website under the Investors section. After the event concludes, a replay will be available approximately one hour later and remain accessible for about a month. This offers a great opportunity for those unable to attend the live event to catch up on important updates.
Commitment to Addressing Unmet Medical Needs
Neurocrine Biosciences prioritizes alleviating suffering in individuals facing significant medical challenges. The company is renowned for its commitment to discovering and developing innovative therapies that target under-addressed neurological, psychiatric, endocrine, and immunological disorders. With an impressive track record, Neurocrine has established a portfolio that includes FDA-approved treatments for issues such as tardive dyskinesia and chorea linked to Huntington's disease.
Current and Future Innovations
Over the last thirty years, Neurocrine has applied its expertise in neuroscience, understanding how the brain and body interact to address complex health conditions. Their research continues to yield promising compounds, many of which are advancing through mid- to late-phase clinical trials. This dedication not only enhances the therapeutic landscape but also offers hope to patients in critical need of effective treatments.
The diverse portfolio underlines Neurocrine's ongoing mission, promoting several treatments aimed at easing symptoms associated with conditions like endometriosis and uterine fibroids. This robust clinical pipeline reflects the company's relentless pursuit of science that empowers patients, proving that they truly believe in their motto: "You deserve brave science."
Stay Informed with Neurocrine Biosciences
For individuals interested in learning more about Neurocrine Biosciences, the company's website features a wealth of resources including information about ongoing research, corporate updates, and investor relations. Engaging with the community through social media platforms, the company encourages interested parties to follow them on LinkedIn, Facebook, Twitter, and YouTube. This initiative helps promote awareness and understanding of the advancements being made in neurological and psychiatric treatments.
Neurocrine's branded commitment is evident. The company's logo and their slogans are not just marketing tools; they're emblematic of a broader mission to enhance the quality of life for those grappling with challenging medical conditions.
Frequently Asked Questions
What is the date for the Neurocrine Biosciences conference call?
The conference call is scheduled for February 11, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
How can I access the webcast?
The webcast can be accessed on Neurocrine Biosciences' official website under the Investors section after the event.
What topics will be covered during the conference call?
The call will address the company's financial results for Q4 and year-end 2025, along with insights into their research and pipeline advancements.
What are some of the approved treatments by Neurocrine?
Neurocrine has FDA-approved treatments for conditions including tardive dyskinesia, chorea associated with Huntington's disease, and endometriosis.
Where can I find more information about Neurocrine Biosciences?
Additional information can be found on the company's website and through their social media channels on platforms such as LinkedIn and Twitter.
